News
10-28-2010, 09:51 PM
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended September 30, 2010 - the first quarter of the Company's 2011 fiscal year (1QFY11).
More... (http://www.news-medical.net/news/20101029/ImmunoGen-first-quarter-net-loss-increases-to-24129-million.aspx)
More... (http://www.news-medical.net/news/20101029/ImmunoGen-first-quarter-net-loss-increases-to-24129-million.aspx)